OKG Capital
To add a bio or update investment portfolio, please click update information.
Investment Portfolio
OXcan
9 Jan 2025
OXcan raises £9m Series A led by We Venture Capital and Cross-Border Impact Ventures to revolutionise early lung cancer detection
OXcan develops blood-based liquid biopsy tests using proteomics and AI to detect lung cancer at earlier stages, enabling minimally invasive screening designed to improve outcomes and reduce pressure on healthcare systems.
52North
6 Dec 2024
Oncology medical tech startup 52North secures £5m with landmark UK-US hospital VC deal
52North builds medical devices and digital tools that support cancer patients outside hospital, focusing on early detection and monitoring of treatment-related complications to improve urgent oncology care pathways.
More venture news
- 10 Jun 2026
Capsa AICapsa AI lands £14m Series A led by TX Ventures and Pivot Investment Partners to build the AI operating system for private capital
Series AAI - 9 Jun 2026
NewOrbitNewOrbit raises £14m in a Series A led by Voyager Ventures to build the first commercial satellites for very low Earth orbit
Series ADeep Tech - 2 Jun 2026
IMU BiosciencesIMU Biosciences unlocks £40m Series A led by IQ Capital and Molten Ventures to decode the immune system with high-resolution blood analysis
Series ALife Sciences
